HCV

Isis Pharmaceuticals has been named as a defendant in an intellectual property lawsuit filed by biopharmaceutical company Gilead Sciences against Merck related to a novel hepatitis C therapeutic.

Regulus Therapeutics remains on track to filing an investigational new drug application for its microRNA-targeting hepatitis C treatment RG-101 next year, with a second candidate — likely for fibrosis or cancer — to be added to the company's formal pipeline before the end of 2013

Alere President and CEO Ron Zwanziger last week provided investors with an update on the development timeline for a pair of point-of-care nucleic acid testing plartforms, the company's first molecular diagnostics products.

Benitec Biopharma announced last week that it has received a written report confirming a favorable review of a planned phase I/IIa clinical trial for its expressed hepatitis C treatment from the National Institutes of Health’s Recombinant DNA Advisory Committee.

Laboratory Corporation of America said this week that it is offering Roche's Cobas AmpliPrep/Cobas TaqMan HCV test, v2.0.

Benitec Biopharma hit two key milestones recently in its effort to advance its expressed RNAi-based hepatitis C treatment TT-034 into the clinic, securing a commitment to sell A$7 million ($6.7 million) of its stock to new and existing shareholders and receiving a favorable revie

Regulus Therapeutics this week announced that it has selected its first drug candidate, RG-101 for the treatment of hepatitis C. However, the company said it will develop the compound on its own despite an ongoing collaboration on the disease with GlaxoSmithKline.